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Momordica charantia, commonly called bitter melon, is a plant belonging to
Cucurbitaceae family known for centuries for its pharmacological activities, and
nutritional properties. Due to the presence of many bioactive compounds, some of
which possess potent biological actions, this plant is used in folk medicine all over the
world for the treatment of different pathologies, mainly diabetes, but also cancer, and
other inflammation-associated diseases. It is widely demonstrated that M. charantia
extracts contribute in lowering glycaemia in patients affected by type 2 diabetes.
However, the majority of existing studies on M. charantia bioactive compounds were
performed only on cell lines and in animal models. Therefore, because the real impact
of bitter melon on human health has not been thoroughly demonstrated, systematic
clinical studies are needed to establish its efficacy and safety in patients. Besides, both
in vitro and in vivo studies have demonstrated that bitter melon may also elicit toxic
or adverse effects under different conditions. The aim of this review is to provide an
overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing
its pharmacological activity as well as the potential adverse effects. Even if a lot of
literature is available about bitter melon as antidiabetic drug, few papers discuss the
anti-inflammatory and anti-cancer properties of this plant.
Keywords: Momordica charantia, bitter melon, bitter gourd, natural products, nutraceuticals, anti-inflammatory
agents, anti-cancer agents
TRADITIONAL USES OF Momordica charantia
Momordica charantia L. (MC), also known as bitter melon or bitter gourd, belongs to Cucurbitaceae
family and grows in tropical and sub-tropical regions. The fruits and leaves of Momordica species
are rich in phytochemicals and may have many health-promoting effects by offering nutritional
and nutraceutical components. The plant has been known for ages and it has been used in many
traditional and folk medicines (Polito et al., 2016a) for a wide range of medical applications,
including the treatment of T2DM, hypertension, obesity, cancer, bacterial and viral infections,
and even AIDS (Grover and Yadav, 2004). In Ayurveda medicine, bitter melon, known as karela,
Abbreviations: ERK, extracellular signal-regulated kinases; IL, interleukin; IT, immunotoxin; JNK, c-Jun N-terminal
kinases; LPS, lipopolysaccharide; MAP30, Momordica anti-viral protein of 30 kDa; MAPKs, mitogen-activated protein
kinases; MC, Momordica charantia; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NO, nitric oxide;
RIP, ribosome-inactivating-protein; T2DM, type 2 diabetes mellitus; TNF-α, tumor necrosis factor-alpha.
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has been used for thousands of years. Its pharmacological
properties are attributed to each part of the plant, i.e., seeds,
roots, leaves, and particularly the unripe fruits (Scartezzini and
Speroni, 2000). The juice found application for the treatment of
many disorders: for example, it is used for joint pain relief and
against chronic fever, in cases of jaundice and illnesses of the
liver or the digestive system because of its diuretic, laxative and
anti-helminthic actions. It is applied locally in case of chronic
skin diseases and to treat burns, boils, and rashes. The use of the
whole plant as food is recommended for the treatment of T2DM
(Scartezzini and Speroni, 2000). In Turkish folk medicine the oil
obtained from the ripe fruits of bitter melon, macerated in olive
oil warmed by the sun, was combined with honey, and used for
the prevention and healing of gastric ulcers (Gürdal and Kültür,
2013). In African folk medicine bitter melon is mainly used
for worm infections, inflammation (fruits, seeds, and leaf juice),
fever, menorrhea (leaves), syphilis, rheumatism, and skin diseases
(roots). Leaf decoction is used in T2DM patients; fruits and leaves
are used for the treatment of jaundice and other liver diseases
and to cure ulcers and burns. Moreover, Momordica preparations
are given for the treatment of gonorrhea, measles, chicken pox,
scabies and malaria. In the Caribbean area, it is administered as a
leaf decoction or fruit juice for the treatment of diabetes. The leaf
decoction is also used for the treatment of high blood pressure,
womb infections, malaria, dysentery, and worm infections. Leaf
baths are used for rheumatism therapy (Polito et al., 2016a).
CHEMICAL CONSTITUENTS AND
NUTRITIONAL VALUE OF
Momordica charantia
The major chemical constituents of MC are classified as: (i)
heteropolysaccharides, mainly composed of galactose, glucose,
arabinose, rhamnose, and mannose; (ii) proteins and peptides,
such as momordins, momorcharins, MAP30 and MC lectin,
belonging to the ribosome-inactivating proteins family (RIPs)
(Schrot et al., 2015); (iii) terpenoids and saponins, such as
cucurbitanes and cucurbitacines; (iv) flavonoids and phenolic
compounds; (v) other compounds such as essential oils, fatty
acids, amino acids, and sterols (Dandawate et al., 2016). Chemical
structures of the main bioactive MC constituents are reported in
Supplementary Figure S1.
Nutritional analysis demonstrated that this plant possesses the
highest nutritive value among cucurbits, being a good source
of carbohydrates, proteins, fibers, vitamins, and minerals. Fruits
are composed by 93.2% of water, while protein and lipids
account for 18.02 and 0.76% of its dried weight, respectively
(Saad et al., 2017). Green fruits contain vitamin C, A and
P, thiamine, riboflavin, niacin, and minerals (Gupta et al.,
2011). In addition, MC seeds can represent a good source of
lipids, such as polyunsaturated fatty acids (nearly 45% of the
weight) and they are among the few foods containing conjugated
linolenic acid, being 63–68% as eleostearic acid (Yoshime et al.,
2016). The essential oil, obtained from drought seeds, contains
sesquiterpenes, phenylpropanoids and monoterpenes. Other
bioactive compounds, such as tocopherols and polyphenols
have been reported in MC seed oil (Nyam et al., 2013). The
pericarp, the aril, the stem and the leaves of the plant are also
a good source of phenolic compounds, which can be useful to
protect from oxidative damage by acting directly on reactive
oxygen species and to induce endogenous defense systems
(Yoshime et al., 2016).
Several glycosides isolated from MC fruit and stem
have been grouped as cucurbitane-type triterpenoids,
being cucurbitacins the main ones. They exhibit a broad
range of biological activities, mainly anti-inflammatory and
anti-diabetic (Rios et al., 2005).
ANTI-INFLAMMATORY AND
ANTI-OXIDANT ACTIVITY OF
Momordica charantia
Lifestyle and dietary habits contribute to a chronic state of low-
grade inflammation, which can alter immune status and gut
microbiota. Various dietary components have the potential to
modulate predisposition to chronic inflammatory conditions and
can be helpful in their therapy. Nevertheless, the relationship
among most of these dietary components and their anti-
inflammatory mechanisms is unclear (Minihane et al., 2015).
Momordica charantia dietary supplementation has been
widely studied to treat several diseases, like T2DM, dyslipidemia,
obesity and cancer, thus showing that MC extracts possess
hypoglycemic and lipid-lowering properties, even if clinical trials
conducted so far gave inconclusive results (Alam et al., 2015). In
diabetic patients, the chronic systemic inflammation contributes
to increase blood glucose concentration and represents a risk
factor in developing cardiovascular diseases and obesity. Chronic
inflammation is involved in the pathogenesis of different diseases:
a clear association has been established for neurodegenerative
diseases, obesity, metabolic syndrome, cardiovascular disease,
T2DM, and cancer (Minihane et al., 2015). Several evidences
indicate that oxidative stress plays a role in chronic inflammatory
diseases. Thus, oxidative stress and inflammation are closely
related pathophysiological processes that can activate each other
(Biswas, 2016). MC beneficial properties seem dependent on its
anti-inflammatory and anti-oxidant activities (Chao et al., 2014;
Dandawate et al., 2016). Various MC extracts were found to
regulate inflammation mainly through NF-κB signaling pathway
inhibition: in RAW 264.7 cells, bitter melon reduced TNF-α
production, induced by LPS, decreasing the expression of LPS-
induced inflammatory genes, including those for IL-1α, IL-1β,
and TNF-α. The MC extracts also reduced NF-κB DNA binding
activity and phosphorylation of p38, JNKs, ERKs as well as
MAPKs (Kobori et al., 2008a). Moreover, MC showed reduction
of LPS-induced NO and prostaglandin E2 production together
with a reduction of inducible NO synthase and IL-1β expression
(Lii et al., 2009). In the same cell model, a dose-dependent
inhibition of NO production for MC extract was demonstrated
(Svobodova et al., 2017); but it was also reported that MC
extracts reduced expression levels of inducible NO synthase and
cyclooxygenase-2, suppressing NF-κB, and activator protein-1
(AP-1) activity via downregulation of ERKs and Akt (Hsu et al.,
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FIGURE 1 | Main mechanisms of Momordica charantia pharmacological effects.
2013; Yang et al., 2018). The effects of a triterpene purified
from bitter melon was investigated against TNF-α-induced
inflammation via AMP-activated protein kinase in FL83B cells.
This compound suppressed the TNF-α-induced expression of
inflammatory markers, including inducible NO synthase, p65
subunit of NF-κB, TNF-α, and IL-1β (Cheng et al., 2012). In
C57BL/6 mice fed with high-fat diet supplemented with MC, a
decrease in serum C reactive protein and IL-6 concentrations
together with a loss of hyperglycemia and hyperlipidemia
was reported (Xu et al., 2014). The MC-containing diet also
normalized serum levels of the cytokines suggesting its role in
reducing inflammation, obesity and insulin resistance in obese
mice (Bao et al., 2013). Dietary supplementation with MC
powder in high-fat diet obese mice was showed to lower systemic
inflammation by reducing TNF-α and IL-6 serum levels and
to remodel key functions of colon by altering transcriptomic
profile and affecting the expression of genes involved in the
regulation of inflammation (Bai et al., 2016, 2018). Recently, it
was reported that MC extracts reduced intercellular adhesion
molecule-1 expression and upregulated mir-221/-222 in TNF-
α treated lung tissues in mice, also decreasing PI3K/Akt/NF-
κB/IκB. MC extracts were given before TNF-α, suggesting
that bitter melon supplementation may be useful as a chemo-
preventive agent in individuals at risk for inflammatory-related
diseases (Sung et al., 2018). Therefore, MC exerts its anti-
inflammatory effects by acting on several important signaling
pathways involved in inflammation.
The potential anti-oxidant activity of MC extracts has
been evaluated in several in vitro studies. Pretreatment
of neuroblastoma cells with MC extracts was found to
attenuate cytotoxic oxidative stress induced by H2O2 by
increasing intracellular scavenger activity and reducing H2O2-
induced activation of the JNKs, p38, and ERK1/2 MAPK
signaling pathways (Kim et al., 2018). MC fruit extract
significantly reduced neuro-inflammation, ameliorating the
consequent neurodegenerative diseases (Nerurkar et al., 2011).
Xanthine oxidase is a key enzyme for the induction of
hyperuricemia and gout and it is involved in many inflammation
related diseases, such as metabolic syndrome, and in augmented
cancer risk (Battelli et al., 2016, 2018). Cucurbitane-type
triterpene glycosides isolated from MC stems and fruits
significantly inhibit xanthine oxidase activity (Lin et al.,
2012). Triterpenoids isolated from MC stems have also shown
scavenging activities and inhibitory effect on xanthine oxidase
activity (Liu et al., 2010). Anti-oxidant compounds in bitter gourd
pulp and seed powders showed potential natural anti-oxidant
activity to inhibit the lipid peroxidation (Padmashree et al.,
2010). Moreover, MC was evaluated for its anti-oxidant activity
in vitro showing an amelioration of oxidative damage induced by
peroxynitrite (Kim et al., 2013). It has been demonstrated that,
after blanching, bitter gourd considerably decreases its phenolic
content and anti-oxidant activity (Myojin et al., 2008). Therefore,
the MC anti-oxidant activity seems dependent both from direct
radical scavenge of MC components and from their effect on
oxidant enzymes.
Bitter melon extracts were also found to alleviate bacterial-
induced inflammation. For example, MC extracts reduced
Propionibacterium acnes-induced skin inflammation in mice and
suppressed the cytokine and matrix metalloproteinase-9 levels in
Propionibacterium acnes-induced inflammation of THP-1 cells.
This activity was attributed to the anti-inflammatory effects
of phenolic compounds present in the extract (Huang et al.,
2015). Cucurbitane triterpenods isolated from MC leaves strongly
suppressed Porphyromonas gingivalis-induced IL-8, IL-6, and
IL-1β levels (Tsai et al., 2016).
The anti-inflammatory activity of MC supplementation
has been also demonstrated in patients with primary knee
osteoarthritis, in a single-blinded, randomized trial. Thirty-eight
patients were daily treated for 3 months with commercially
available MC supplementation. After 3 months, there were
significant improvements in knee osteoarthritis and reduction in
analgesic score; also, body weight, body mass index, and fasting
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TABLE 1 | Main anti-oxidant and anti-inflammatory studies carried out in vitro and in vivo with MC components.
Pathological
process
Compound(s) In vitro Animals References
Inflammation MC extract Mice Deng et al., 2019
Oxidative stress MC ethanol extract SK-N-MC cells Kim et al., 2018
Oxidative stress MC leaf ethanol extract Obese mice He et al., 2018
Inflammation MC extracts ApoE KO C57BL/6 mice Zeng et al., 2018
Inflammation MC powder Obese Sprague-Dawley
rats
Bai et al., 2016, 2018
Inflammation MC fruit extracts A549 cells C57BL/6 mice Sung et al., 2018
Oxidative
stress/inflammation
Bioactive peptide BG-4 THP-1 cells Jones et al., 2018
Oxidative
stress/inflammation
MC methanol extract RAW264.7 cells Lii et al., 2009; Yang et al.,
2018
Oxidative
stress/inflammation
MC polysaccharides Oxidative stress cell free assays
Primary neuronal cells
Gastritis/myocardial
infarction/ischemia-
reperfusion/rat
models
Gong et al., 2015; Tan and
Gan, 2016; Raish, 2017; Raish
et al., 2018
Inflammation MC fruit juice T-cells Diabetic Wistar rats Fachinan et al., 2017a,b
Oxidative
stress/inflammation
MC extract Holstein-Friesian cows Emre et al., 2017
Oxidative stress MC anthocyanins Oxidative stress cell free assays Güdr, 2016
Oxidative stress MC extract Oxidative stress cell free assays Padmashree et al., 2010;
Ghous et al., 2015; Aljohi et al.,
2016
Oxidative stress MC metanolic, ethanolic and
butanolic extracts
Oxidative stress cell free assays Yadav et al., 2016
Inflammation MC leaf extract Porphyromonas gingivalis-induced
THP-1 stimulation
Mice skin inflammation
model
Huang et al., 2015; Tsai et al.,
2016
Inflammation MC fruit and seeds extract BALB/c mice with sepsis Chao et al., 2014; Ciou et al.,
2014
Inflammation MC fruit ethyl acetate extract RAW 264.7 cells Hsu et al., 2013
Inflammation MC fruits Obese C57BL/6 mice Bao et al., 2013
Inflammation Cucurbitane-type triterpene RAW 264.7 cells; FL83B cells Cheng et al., 2012; Liaw et al.,
2015
Oxidative
stress/inflammation
MC aqueous extracts Obese mice; Diabetic rats Tripathi and Chandra, 2010; Xu
et al., 2014
Inflammation Butanol extract RAW 264.7 cells Kobori et al., 2008a
blood glucose were significantly reduced. In this study, it was
demonstrated that MC can represent an alternative to reducing
pain and improving symptoms among patients while reducing
the need for analgesic drug consumption (Soo May et al., 2018).
The main mechanisms of MC anti-inflammation and anti-
oxidant actions are summarized in Figure 1. In Table 1 we
summarized some of the main in vitro and in vivo studies
conducted so far to investigate MC anti-inflammation and anti-
oxidant actions.
ANTI-CANCER ACTIVITY OF
Momordica charantia
Accumulating evidence shows that chronic inflammation can
promote tumor initiation and malignant progression of many
cancers. Two pathways linking inflammation and cancer are
generally identified: (i) tumor-extrinsic inflammation, which
is caused by many factors, including bacterial and viral
infections, lifestyle and exposure to environmental pollutant,
and it is mediated by innate immunity cells; (ii) tumor-intrinsic
inflammation, which is due to neoplastic mutations leading to
the production of inflammatory mediators and the recruitment
of immunity cells in the tumor microenvironment, contributing
in an inflammatory milieu promoting several steps of cancer
progression. These two pathways share common features, such as
the production of primary inflammatory cytokines like IL-1, IL-
6, and TNF-α and the activation of known transcription factors
involved in the regulation of inflammatory response, such as NF-
κB and STAT3 (Marelli et al., 2017). Considering the importance
of inflammatory changes in different cancer types, preventing or
reversing inflammation has become an important approach to
control neoplasia progression.
In Table 2 we summarized some of the main in vitro
and in vivo studies conducted so far to investigate MC anti-
cancer activity.
Several phytochemicals, including MC extracts, are described
to possess promising potentials as adjuvants in conventional
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TABLE 2 | Main anti-tumoral studies carried out in vitro and in vivo with MC components.
Tumor Compound(s) Cells Animals References
Breast Cucurbitane-type triterpene MCF-7, MDA-MB-231 Weng et al., 2013
RNase MC2 MCF-7 Fang et al., 2012a
MC extract MCF-7, MDA-MB-231 Ray et al., 2010
Eleostearic acid MDA-ERα7 Grossmann et al., 2009
Water MC extract SHN mice Nagasawa et al., 2002
MAP30 MDA-MB-231 SCID mice Lee-Huang et al., 2000
α-momorcharin MCF-7, MDA-MB-231, MDAMB-453 Balb/C mice Cao et al., 2015
Colon Methanol MC extract HT-29, SW480, HFF Kwatra et al., 2013
Methanol MC extract Hone-1, AGS, HCT-116, CL1-0 Li et al., 2012a
Acid and alkali MC extracts SGC-7901 Li et al., 2012b
MAP30 LoVo Fan et al., 2008
MC fatty acids Caco-2 Yasui et al., 2005
MC extract Swiss mice Deep et al., 2004
MC extract F344 rats Kohno et al., 2004
Liver MAP30 Hep G2 Balb/C nude mice Fang et al., 2012b
RNase MC2 Hep G2 Balb/C nude mice Fang et al., 2012c
MC lectin Hep G2, PLC/PRF/5 Nude mice Zhang et al., 2015
Cucurbitane-type triterpene glycosides Hep G2, Hep 3B Yue et al., 2019
Prostate MC extract PC3, LNCaP TRAMP mice Ru et al., 2011
MC leaf extract, Kuguacin J LNCaP, PNT1A Pitchakarn et al., 2011
MC leaf extract PLS10 Nude mice Pitchakarn et al., 2010
MCP30 LNCaP, PC-3, RWPE-1, PIN Nude mice Xiong et al., 2009
Bladder 48–127/momordin IT T24 Battelli et al., 1996
Glioma Transferrin/momordin IT HS683, U251 Gosselaar et al., 2002
Lymphoma Ber-H2/momordin IT ALCL SCID mice Terenzi et al., 1996
OM124/momordin IT Daudi, EHM, BJAB, Raji, BM21 SCID mice Bolognesi et al., 1998
Leukemia Ethanol MC extracts ED, Su9T01, S1T, HUT-102, MT-2,
Jurkat, MOLT-4
Kai et al., 2011
Ethanol MC extracts HL60 Balb/cAnNCrj-nu/nu mice Kobori et al., 2008b
Anti-CD5/momordin IT Peripheral blood mononuclear cells,
Jurkat
nu/nu mice Porro et al., 1993
anticancer therapies, due to their ability to prevent cancer
progression (Salehi et al., 2018). MC extracts have been
investigated mainly for their potential use as chemo-preventive
agents; many studies have evaluated the efficacy of MC
extracts or purified components against different tumor derived
cells, suggesting that dietary consumption of MC could
help to lower risk of several cancers. Anti-proliferative and
immunomodulatory effects were reported in the majority of
studies (Nerurkar and Ray, 2010). It is thought that MC
extracts’ anti-cancer properties could rely on the ability to
modulate several de-regulated signaling pathways in different
type of cancer, like MAPK pathway, Akt/mTOR/p70S6K pathway
through activation of AMPK, Wnt/β-catenin signaling pathway
and through the modulation of cell cycle proteins, thereby
inducing cell cycle arrest or inducing apoptosis or other cell
death pathways. Three recently identified MC cucurbitane-
type triterpene glycosides showed significant anti-tumor activity
in hepatic carcinoma derived cell lines (Yue et al., 2019).
Given the influence of MC extracts on several inflammatory-
related signaling pathways, it is possible that MC anti-
inflammatory properties may play a major role in its efficacy
as tumor-preventive agent (Farooqi et al., 2018). To date,
anti-cancer activity has been only observed in cancer cell
lines and xenografted mice, and there is a need of further
studies to elucidate the possible use of MC extracts as
nutraceuticals in the treatment of cancer. A significant anti-
tumor activity was reported for some MC proteins belonging
to RIP family (Bolognesi et al., 2016). These proteins are
potent inhibitors of cell translation and they have been
extensively used for the production of anti-cancer drugs,
particularly in the form of immunoconjugates or ITs, to
obtain selective toxic protein delivery to target malignant cells
(Polito et al., 2016b).
Although the lack of clinical data demonstrating the anti-
tumor effect of MC components on humans, the whole results
available in the literature make highly plausible a protective
effect of MC both in the initiation of the tumor cell and during
tumor progression. It is well known that the initial neoplastic
transformation can be favored by oxidative stress that could
be prevented by MC components. Tumor progression toward
malignity is strongly related to chronic inflammation that is
responsible for tumor invasion of surrounding normal tissues
and angiogenesis. Again, the MC components could exert their
anti-tumor effects by modulation of the inflammation status.
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The main mechanisms of MC anti-tumor action are
summarized in Figure 1.
SAFETY OF Momordica charantia
Despite the wide MC usage in several traditional medicine,
mainly for T2DM, there are quite scarce data from clinical trials
and the few published studies enrolled a limited number of
patients, for these reasons, safety data are more often derived
from animal models. This lack of standardization in clinical
studies still represents a limitation in the recognition of the
therapeutic value of MC by a part of the scientific community.
MC efficacy and safety have been comprehensively described
by Basch et al. (2003). A recent meta-analysis highlighted the
scarcity of data from clinical trials and the need for more
structured and well-conducted studies (Peter et al., 2019).
Momordica charantia drugs should be always avoided by
subjects that reported allergy to other plants from Cucurbitaceae.
Individuals with glucose-6-phosphate dehydrogenase deficiency
can develop favism after MC consumption (Raman and Lau,
1996). People wishing to procreate should consider with caution
the daily use of MC, as it strongly reduced fertility in animal
models (Stepka et al., 1974). As well as great caution should be
used in the consumption of MC during pregnancy, since proteins
contained in MC extracts showed abortive properties in animals
(Basch et al., 2003). Caution is required also in patients with
liver disease, because transaminase augment, although without
histopathological alterations, was reported in animals. The most
serious adverse effects in humans were reported in two small
children that experienced a strong reduction of glycaemia after
drinking MC based beverage on an empty stomach: between 1
and 2 h after ingestion, the children had convulsions followed
by hypoglycemic coma (Raman and Lau, 1996). Other data on
pediatric dosages are lacking.
A case of acute interstitial nephritis was reported in a 60-
years male with T2DM and hypertension that used hyponidd,
an ayurvedic drug containing M. charantia. The patient took
one hyponidd tablet daily for 1 week before the onset of his
symptoms: edema and a decrease in urine, which progressed to
complete anuria in 2–3 days (Beniwal et al., 2017). The toxicity
for kidney was already reported in mice treated with MC 4 g/kg
for more than a week (Mardani et al., 2014).
CONCLUSION
About two third of world population continue to prefer local
folk medicine to industrial drugs, mainly for economic reasons
but in many cases also because of the fidelity to a traditional
life style. The interest in plant derived medicinal products is
increasing also in the occidental countries because these kinds of
drugs are considered more “natural” and thus less toxic (often
erroneously). Bitter melon is commonly used as a natural drug,
mainly for the treatment of T2DM, but also as anti-inflammatory
and anti-oxidant. It is well known the MC contribute in lowering
glycaemia in T2DM patients. Moreover, the above reported
researches attesting the MC anti-inflammatory effects seem to
indicate the possible contribute of MC preparations also to reduce
analgesic drug consumption in inflammatory related diseases.
However, it should be considered that the variability of
preparation and the differences in cultivar and plant variety, the
stage of harvest, the part of plant used and other factors can
contribute to the discordant findings across the literature and
often make difficult to fix the optimal dosage in terms of both
efficacy and safety.
In addition, some considerations should be taken into account
about MC side effects and interaction with conventional drugs:
(i) for patients assuming MC at high doses and for prolonged
periods clinical signs attributable to renal distress should not be
underestimated; (ii) caution should be used when MC is taken
together with other blood glucose-reducing agents because of the
possible additive effects.
In conclusion, more trials are necessary to establish MC
efficacy and safety with the aim to better utilize this precious
natural resource.
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